219 related articles for article (PubMed ID: 21693105)
1. Neuraminidase inhibitor R-125489--a promising drug for treating influenza virus: steered molecular dynamics approach.
Mai BK; Li MS
Biochem Biophys Res Commun; 2011 Jul; 410(3):688-91. PubMed ID: 21693105
[TBL] [Abstract][Full Text] [Related]
2. Binding pattern of the long acting neuraminidase inhibitor laninamivir towards influenza A subtypes H5N1 and pandemic H1N1.
Meeprasert A; Khuntawee W; Kamlungsua K; Nunthaboot N; Rungrotmongkol T; Hannongbua S
J Mol Graph Model; 2012 Sep; 38():148-54. PubMed ID: 23079644
[TBL] [Abstract][Full Text] [Related]
3. Dynamic behavior of avian influenza A virus neuraminidase subtype H5N1 in complex with oseltamivir, zanamivir, peramivir, and their phosphonate analogues.
Udommaneethanakit T; Rungrotmongkol T; Bren U; Frecer V; Stanislav M
J Chem Inf Model; 2009 Oct; 49(10):2323-32. PubMed ID: 19780597
[TBL] [Abstract][Full Text] [Related]
4. Infiltration of water molecules into the oseltamivir-binding site of H274Y neuraminidase mutant causes resistance to oseltamivir.
Park JW; Jo WH
J Chem Inf Model; 2009 Dec; 49(12):2735-41. PubMed ID: 19957991
[TBL] [Abstract][Full Text] [Related]
5. Source of oseltamivir resistance in avian influenza H5N1 virus with the H274Y mutation.
Malaisree M; Rungrotmongkol T; Nunthaboot N; Aruksakunwong O; Intharathep P; Decha P; Sompornpisut P; Hannongbua S
Amino Acids; 2009 Oct; 37(4):725-32. PubMed ID: 19002747
[TBL] [Abstract][Full Text] [Related]
6. Insights from investigating the interaction of oseltamivir (Tamiflu) with neuraminidase of the 2009 H1N1 swine flu virus.
Wang SQ; Du QS; Huang RB; Zhang DW; Chou KC
Biochem Biophys Res Commun; 2009 Aug; 386(3):432-6. PubMed ID: 19523442
[TBL] [Abstract][Full Text] [Related]
7. Mutation-induced loop opening and energetics for binding of tamiflu to influenza N8 neuraminidase.
Kar P; Knecht V
J Phys Chem B; 2012 May; 116(21):6137-49. PubMed ID: 22553951
[TBL] [Abstract][Full Text] [Related]
8. Theoretical studies on the susceptibility of oseltamivir against variants of 2009 A/H1N1 influenza neuraminidase.
Li L; Li Y; Zhang L; Hou T
J Chem Inf Model; 2012 Oct; 52(10):2715-29. PubMed ID: 22998323
[TBL] [Abstract][Full Text] [Related]
9. Laninamivir and its prodrug, CS-8958: long-acting neuraminidase inhibitors for the treatment of influenza.
Yamashita M
Antivir Chem Chemother; 2010; 21(2):71-84. PubMed ID: 21107016
[TBL] [Abstract][Full Text] [Related]
10. Study of drug resistance of chicken influenza A virus (H5N1) from homology-modeled 3D structures of neuraminidases.
Wang SQ; Du QS; Chou KC
Biochem Biophys Res Commun; 2007 Mar; 354(3):634-40. PubMed ID: 17266937
[TBL] [Abstract][Full Text] [Related]
11. Understanding the cross-resistance of oseltamivir to H1N1 and H5N1 influenza A neuraminidase mutations using multidimensional computational analyses.
Singh A; Soliman ME
Drug Des Devel Ther; 2015; 9():4137-54. PubMed ID: 26257512
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of the new neuraminidase inhibitor CS-8958 against H5N1 influenza viruses.
Kiso M; Kubo S; Ozawa M; Le QM; Nidom CA; Yamashita M; Kawaoka Y
PLoS Pathog; 2010 Feb; 6(2):e1000786. PubMed ID: 20195462
[TBL] [Abstract][Full Text] [Related]
13. Design of multi-binding-site inhibitors, ligand efficiency, and consensus screening of avian influenza H5N1 wild-type neuraminidase and of the oseltamivir-resistant H274Y variant.
García-Sosa AT; Sild S; Maran U
J Chem Inf Model; 2008 Oct; 48(10):2074-80. PubMed ID: 18847186
[TBL] [Abstract][Full Text] [Related]
14. In silico identification of the potential drug resistance sites over 2009 influenza A (H1N1) virus neuraminidase.
Liu H; Yao X; Wang C; Han J
Mol Pharm; 2010 Jun; 7(3):894-904. PubMed ID: 20420444
[TBL] [Abstract][Full Text] [Related]
15. Recent advances in neuraminidase inhibitor development as anti-influenza drugs.
Feng E; Ye D; Li J; Zhang D; Wang J; Zhao F; Hilgenfeld R; Zheng M; Jiang H; Liu H
ChemMedChem; 2012 Sep; 7(9):1527-36. PubMed ID: 22807317
[TBL] [Abstract][Full Text] [Related]
16. Insights into susceptibility of antiviral drugs against the E119G mutant of 2009 influenza A (H1N1) neuraminidase by molecular dynamics simulations and free energy calculations.
Pan P; Li L; Li Y; Li D; Hou T
Antiviral Res; 2013 Nov; 100(2):356-64. PubMed ID: 24055835
[TBL] [Abstract][Full Text] [Related]
17. Molecular basis of drug resistance in A/H1N1 virus.
Vergara-Jaque A; Poblete H; Lee EH; Schulten K; González-Nilo F; Chipot C
J Chem Inf Model; 2012 Oct; 52(10):2650-6. PubMed ID: 22978683
[TBL] [Abstract][Full Text] [Related]
18. Study of Tamiflu sensitivity to variants of A/H5N1 virus using different force fields.
Nguyen TT; Mai BK; Li MS
J Chem Inf Model; 2011 Sep; 51(9):2266-76. PubMed ID: 21834591
[TBL] [Abstract][Full Text] [Related]
19. A new and rapid genotypic assay for the detection of neuraminidase inhibitor resistant influenza A viruses of subtype H1N1, H3N2, and H5N1.
Duwe S; Schweiger B
J Virol Methods; 2008 Nov; 153(2):134-41. PubMed ID: 18725246
[TBL] [Abstract][Full Text] [Related]
20. Analogue inhibitors by modifying oseltamivir based on the crystal neuraminidase structure for treating drug-resistant H5N1 virus.
Du QS; Wang SQ; Chou KC
Biochem Biophys Res Commun; 2007 Oct; 362(2):525-31. PubMed ID: 17707775
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
